Biomaterial Database

[Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma]. 2006

Qiu-xu Wang, and Tian-xiang Wang, and Chang-fu Sun, and Jing Zhang

Department of Oral and Maxillofacial Surgery, Second Hospital of China Medical University, Shenyang 110004, Liaoning Province, China. qiuxvwang@hotmail.com

OBJECTIVE To study the expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma (TSCC). METHODS The expressions of uPA and uPAR at protein level were examined in 74 cases of TSCC and 15 cases of normal peripheral tissues around cancer (as control) by strep avidin-biotin complex (SABC) immunohistochemical technique. The relationship between the expressions of uPA and uPAR was evaluated by the Spearman's rank correlation test. Mann-Whitney U-test was used to examine the association of these factors with conventional clinical pathological factors. Pearson's Chi-square test was used to analyze the relationship between uPA, uPAR and cervical lymph node status. RESULTS The rates of the positive expression in TSCC of uPA and uPAR were 71.6% and 64.8% respectively, and a positive relationship between expression of uPA and uPAR was found (P<0.05). There was significant correlation between the level of uPA expression and TNM stage or cervical lymph node status, either between the level of uPAR expression and cervical lymph node status. Pathological grade was not significantly related to the level of uPA expression. Pathological grade and TNM stage were not significantly related to the level of uPAR expression. TSCC cases with concurrent positive expression of these proteins revealed significant higher tendency of cervical lymph node metastasis than those with concourse negative expression (P<0.05). CONCLUSIONS The expression of uPA and uPAR increased in TSCC, and uPA, uPAR may contribute significantly to TSCC invasion and metastasis.

UI	MeSH Term	Description	Entries
D008207	Lymphatic Metastasis	Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.	Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D002294	Carcinoma, Squamous Cell	A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014062	Tongue Neoplasms	Tumors or cancer of the TONGUE.	Cancer of Tongue,Tongue Cancer,Cancer of the Tongue,Neoplasms, Tongue,Cancer, Tongue,Cancers, Tongue,Neoplasm, Tongue,Tongue Cancers,Tongue Neoplasm
D014568	Urokinase-Type Plasminogen Activator	A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES.	Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator
D016022	Case-Control Studies	Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time.	Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D055293	Receptors, Urokinase Plasminogen Activator	An extracellular receptor specific for UROKINASE-TYPE PLASMINOGEN ACTIVATOR. It is attached to the cell membrane via a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE and plays a role in the co-localization of urokinase-type plasminogen activator with PLASMINOGEN.	Antigens, CD87,Urokinase Plasminogen Activator Receptor,Urokinase Type Plasminogen Activator Receptor,Urokinase-Type Plasminogen Activator Receptor,CD87 Antigen,Plasminogen Activator Receptor, Urokinase Type,Plasminogen Activator, Urokinase Receptor,Plasminogen Activator, Urokinase Receptors,Receptor, Pro-Urokinase,Receptor, Urokinase Plasminogen Activator,U-PA Receptor,Upar Receptor,Urokinase Plasminogen Activator Receptors,Urokinase-Type Plasminogen Activator Receptors,Antigen, CD87,CD87 Antigens,Pro-Urokinase Receptor,Receptor, Pro Urokinase,Receptor, U-PA,Receptor, Upar,U PA Receptor,Urokinase Type Plasminogen Activator Receptors